We use Google Analytics to see which pages are read and how the site is used, so we know what to improve. This only runs if you accept. See our privacy notice for details.

Dáil

Written answer

Medicinal Products

1835. Deputy Mark Ward asked the Minister for Health if she will expedite the assessment and approval process for a medication (details supplied); if she will ensure timely and equitable access to this treatment for all eligible patients; if she will engage with clinicians, patient organisations, and other relevant stakeholders to address barriers to access. [76042/26]

Comment on this

Under the Health (Pricing and Supply of Medical Goods) Act 2013, the HSE has statutory responsibility for decisions on the pricing and reimbursement of medicines and medical devices.

The HSE has advised that it is committed to providing access to as many medicines as possible, in as timely a fashion as possible, from the resources available (provided) to it.

The HSE must robustly assess applications for pricing and reimbursement to make sure that it can stretch available resources as far as possible and to deliver the best value in relation to each medicine and ultimately more medicines to Irish citizens and patients.

HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds.

The HSE robustly assesses applications for pricing and reimbursement to make sure that it can stretch available resources as far as possible and to deliver the best value in relation to each medicine and ultimately more medicines to Irish citizens and patients.

There are formal processes which govern applications for the pricing and reimbursement of medicines, and new uses of existing medicines, to be funded and / or reimbursed. HSE decisions on which medicines are reimbursed by the taxpayer are made on objective, scientific and economic grounds.

The Drugs Group is the national committee which the HSE has in place to make recommendations on the pricing and reimbursement of medicines. The membership of the HSE Drugs Group includes public interest members. Pharmacoeconomic reports are reviewed by the HSE Drugs Group along with the outputs of commercial negotiations, and any patient group submission(s) received. The HSE Drugs Group considers all of the evidence and makes a recommendation to the HSE Senior Leadership Team.

The decision-making authority in the HSE is the Senior Management Team (HSE SMT). The HSE Senior Management Team decides on the basis of all the demands it is faced with (across all services) whether it can fund a new medicine, or new use of an existing medicine, from the resources that have been provided to it in line with the Health (Pricing and Supply of Medical Goods) Act 2013.

In terms of the specific details of the application for pricing and reimbursement of Belzutifan (Welireg®):

The HSE received an application for pricing / reimbursement on the 6th March 2025 from Merck Sharp & Dohme B.V.(the applicant) for Belzutifan (Welireg®) indicated as a monotherapy for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system ( CNS ) haemangioblastomas, or pancreatic neuroendocrine tumours (pNET) and for whom localised procedures are unsuitable.

The first step in the process is the submission of a Rapid Review dossier (a clinical and economic dossier) to the National Centre for Pharmacoeconomics (NCPE) for assessment. The HSE commissioned the Rapid Review process on the 6th March 2025.

The NCPE Rapid Review assessment report was received by the HSE on the 31st March 2025. The NCPE advised the HSE that a full Health Technology Assessment (HTA) was recommended to assess the clinical effectiveness and cost effectiveness of Belzutifan (Welireg®) compared with the current standard of care.

The HSE commissioned a full HTA on the 30th of April 2025 as per agreed processes.

The HTA was completed by the NCPE on the 25th of May 2026. The NCPE recommends that Belzutifan (Welireg®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments [Belzutifan (Welireg®). HTA ID: 25020 | National Centre for Pharmacoeconomics]

The HSE Corporate Pharmaceutical Unit (CPU) is the interface between the HSE and the Pharmaceutical Industry in relation to medicine pricing and reimbursement applications.

The HSE CPU met with the applicant to discuss the application for Belzutifan (Welireg®) indicated for the treatment of adult patients with von Hippel-Lindau disease who require therapy for associated, localised renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localised procedures are unsuitable. A proposal has been received from the applicant and is under review. The output of negotiations will be presented to the HSE Drugs Group for consideration.

The application remains under consideration with the HSE. The HSE cannot make any comment on possible outcomes from the ongoing process.

Comment on this